How are companies like Viatris, AstraZeneca, Eli Lilly and Company, and Amgen set to revolutionize the Acute Myocardial Infarction market?

LAS VEGAS , NV, UNITED STATES, December 5, 2024 /EINPresswire.com/ -- DelveInsight's “Acute Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2034” report provides a comprehensive analysis of Acute Myocardial Infarction (AMI), delivering a detailed overview of its historical and projected epidemiology. This report also explores evolving market trends and dynamics across major healthcare markets, including the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan. By offering a blend of insights into current treatment landscapes, unmet needs, and emerging therapies, the report serves as a valuable resource for stakeholders aiming to understand and navigate the complexities of the AMI market.

Dive into key insights on the Acute Myocardial Infarction market, trends, and treatments here: Acute Myocardial Infarction Market Forecast Analysis

Key Facts and Analysis of the Acute Myocardial Infarction Market Report:

The Acute Myocardial Infarction (AMI) market size in the 7MM was USD 1.6 billion in 2023, and growth is expected during the forecast period.
Total incident cases of AMI in the 7MM were approximately 1.4 billion in 2023.
NSTEMI cases are more prevalent than STEMI, with NSTEMI accounting for approximately 607K cases in the United States in 2023.
In the United States, total incident cases of AMI were estimated at ~822K in 2023, with cases expected to rise by 2034.
In Japan, there were ~45K STEMI and ~34K NSTEMI cases in 2023.
In 2023, the total number of incident cases of AMI in the EU4 and the UK was ~930Kfor males and ~537K for females.
March 2024: The PATHFAST hs-cTnI-II, a breakthrough high-sensitivity troponin assay, received 510(k) clearance from the U.S. FDA for rapid, accurate diagnosis of myocardial infarction at the point of care.
June 2024: AliveCor received FDA clearance for KAI 12L AI technology and the Kardia 12L ECG System, the first AI-powered handheld 12-lead ECG system capable of detecting serious cardiac conditions, including heart attacks.
Idorsia Pharmaceuticals, Viatris, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Amgen, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, Recardio, CeleCor Therapeutics, Kancera, CellProthera, BioCardia, Mesoblast, and others.
Selatogrel, Dutogliptin, Olpasiran, FDY-5301, Ziltivekimab, Milvexian, Zalunfiban, KAND567, ProtheraCytes, and others.
The AMI market is expected to grow steadily, driven by increased incident cases, ongoing research, and the introduction of new therapies and diagnostic technologies.

Acute Myocardial Infarction Overview

Acute Myocardial Infarction (AMI), commonly referred to as a heart attack, occurs when a coronary artery is suddenly obstructed, leading to damage or death of the heart muscle (myocardial necrosis). Symptoms often include chest discomfort, shortness of breath, nausea, and excessive sweating. Diagnosis is confirmed using electrocardiography (ECG) and cardiac biomarkers. AMI is categorized into two main types: ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI). While STEMI involves significant ECG changes and full-thickness heart damage, NSTEMI features partial damage without classic ECG abnormalities.

Treatment for AMI focuses on restoring blood flow and minimizing further damage through antiplatelet drugs, anticoagulants, nitrates, beta-blockers, and statins. Reperfusion therapies, such as fibrinolytic drugs, percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG), are essential for STEMI patients. For NSTEMI, PCI or CABG is used depending on the severity of the blockage. Despite advancements in treatment, AMI remains one of the leading causes of death in developed nations, highlighting the ongoing need for innovation in prevention and care.

Acute Myocardial Infarction Epidemiology

The Acute Myocardial Infarction epidemiology chapter in the report offers a comprehensive analysis of both historical and forecasted data. It covers the 7MM market, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, with insights spanning from 2020 to 2034. This detailed breakdown provides a clear understanding of the disease's prevalence and trends across key regions.

The Acute Myocardial Infarction market report provides an epidemiological analysis for the period 2020–2034 across the 7MM, segmented by:

Total Incident Cases
Type-specific Incident Cases
Gender-specific Incident Cases

Acute Myocardial Infarction Pipeline Development Activities

The Acute Myocardial Infarction (AMI) market report provides a comprehensive analysis of both approved drugs and late-stage pipeline therapeutics, including those in Phase III, Phase IIa, and Phase II trials. This in-depth evaluation highlights the evolving landscape of AMI treatment options.
The drug chapters offer detailed insights into various aspects of AMI clinical trials, such as the therapies' pharmacological mechanisms, regulatory designations, approval statuses, and patent landscapes. They also include a critical assessment of each drug's benefits and limitations. Additionally, the section features the latest news updates and press releases related to AMI treatments, providing a dynamic overview of advancements in this field.

Acute Myocardial Infarction Therapies and Key Companies

JARDIANCE: Boehringer Ingelheim/ Eli Lilly and Company
Selatogrel: Idorsia Pharmaceuticals
CSL112: CSL Behring
Dutogliptin: Recardio
Milvexian: Janssen Pharmaceutical/Bristol Myers Squibb

Uncover the Future of Acute Myocardial Infarction Treatments – Explore the Emerging Drug Landscape Today!

Scope of the Acute Myocardial Infarction Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Acute Myocardial Infarction Companies: Idorsia Pharmaceuticals, Viatris, AstraZeneca, Boehringer Ingelheim and Eli Lilly and Company, Amgen and Arrowhead Pharmaceuticals, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, Novo Nordisk, Bristol Myers Squibb and Johnson & Johnson Innovative Medicine, Recardio, CeleCor Therapeutics, Kancera, CellProthera and BioCardia, Mesoblast, Boehringer Ingelheim, and others.
Key Acute Myocardial Infarction Therapies: Selatogrel, JARDIANCE, CSL112, Dutogliptin, Olpasiran, FDY-5301, Ziltivekimab, Milvexian, Zalunfiban, KAND567, ProtheraCytes, and others.
Acute Myocardial Infarction Therapeutic Assessment: Acute Myocardial Infarction current marketed and Acute Myocardial Infarction emerging therapies
Acute Myocardial Infarction Market Dynamics: Acute Myocardial Infarction market drivers and Acute Myocardial Infarction market barriers.
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Acute Myocardial Infarction Unmet Needs, KOL’s views, Analyst’s views, Acute Myocardial Infarction Market Access and Reimbursement

Table of Contents

1. Acute Myocardial Infarction Market Report Introduction
2. Executive Summary for Acute Myocardial Infarction
3. SWOT analysis of Acute Myocardial Infarction
4. Acute Myocardial Infarction Patient Share (%) Overview at a Glance
5. Acute Myocardial Infarction Market Overview at a Glance
6. Acute Myocardial Infarction Disease Background and Overview
7. Acute Myocardial Infarction Epidemiology and Patient Population
8. Country-Specific Patient Population of Acute Myocardial Infarction
9. Acute Myocardial Infarction Current Treatment and Medical Practices
10. Acute Myocardial Infarction Unmet Needs
11. Acute Myocardial Infarction Emerging Therapies
12. Acute Myocardial Infarction Market Outlook
13. Country-Wise Acute Myocardial Infarction Market Analysis (2020–2034)
14. Acute Myocardial Infarction Market Access and Reimbursement of Therapies
15. Acute Myocardial Infarction Market Drivers
16. Acute Myocardial Infarction Market Barriers
17. Acute Myocardial Infarction Appendix
18. Acute Myocardial Infarction Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Report:

Myocardial Infarction Pipeline Report

DelveInsight’s "Myocardial Infarction - Pipeline Insight, 2024" report offers an in-depth analysis of a wide range of companies and pipeline drugs within the Myocardial Infarction landscape. It provides detailed profiles of pipeline drugs, covering both clinical and preclinical stage products. The report also includes a comprehensive therapeutics assessment by product type, development stage, route of administration, and molecule type, while highlighting inactive pipeline products in this area.

About DelveInsight

DelveInsight is a prominent consulting and market research firm in the healthcare sector. It specializes in providing comprehensive end-to-end solutions to pharmaceutical companies. Its services aim to enhance the performance of pharmaceutical businesses by offering strategic insights, data-driven analysis, and actionable recommendations.

Their expertise extends to healthcare consulting services, where they assist in market analysis, enabling companies to navigate challenges and drive business growth. By focusing on the life sciences industry, DelveInsight helps organizations make informed decisions, optimize their operations, and accelerate success in a competitive market.

Jatin Vimal
DelveInsight Business Research LLP
+1 469-945-7679
info@delveinsight.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.